Clinical Trials Logo

Vaginal Atrophy clinical trials

View clinical trials related to Vaginal Atrophy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05627791 Terminated - Vaginal Atrophy Clinical Trials

Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Start date: November 30, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Vulvovaginal atrophy affects around 90% of postmenopausal women who may present with symptoms such as dryness, irritation, itching, burning, and dyspareunia that negatively affect the quality of life. Topical estrogen is recommended for the treatment of vulvovaginal atrophy in postmenopausal women and the FDA approved it. But it may increase the risk of breast and endometrial cancer. The oxytocin hormone also promotes positive social behavior, stress regulation, and female sexual arousal. Many previous studies show that topical oxytocin is useful for reducing vaginal atrophy in postmenopausal women.

NCT ID: NCT05458375 Terminated - Clinical trials for Urinary Incontinence

Vaginal Estradiol Use in Pessary Care

Start date: December 29, 2022
Phase: Early Phase 1
Study type: Interventional

The primary outcome of this study compare the rate of pessary discontinuation at 6 months post-pessary fitting in women using vaginal estradiol versus those not using vaginal estradiol.

NCT ID: NCT01753102 Terminated - Vaginal Atrophy Clinical Trials

Efficacy and Safety Of Spil's Estradiol Vaginal Tablet

Start date: November 6, 2012
Phase: Phase 3
Study type: Interventional

Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing 17ß-estradiol. The estradiol in estradiol vaginal tablet is chemically and biologically identical to the endogenous human estradiol and is therefore classified as a human estrogen. The purpose of this study is to demonstrate clinical endpoint bioequivalence of SPIL's Estradiol vaginal tablet, 10mcg estradiol to the reference listed drug (Vagifem®)which is approved and marketed in the US.